The nation of Zimbabwe has rejected a substantial US health deal worth $367m (£272m) over five years over Washington's request for confidential information.
This rejection came to light after a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
An official representative has since explained that the United States was seeking health data for scientific study and profit while was unwilling to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further negotiations to reach a deal suitable to both sides so the nation's vital HIV programme can proceed.
Wider Background
This development follows a similar situation in Kenya, where a court suspended a similar health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 African countries have so far signed similar agreements, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, without any corresponding promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Put simply, our nation would supply the raw materials for medical research without any assurance that the end products would be available to our people if a new disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting frameworks already set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This system is designed to ensure that when a nation contributes its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage ongoing dialogue with our American counterparts on how future collaboration might be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but suggested that talks need to persist given that a large portion of the country's HIV programmes depended on external financing.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
This impasse highlights the complex debate between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.